Late Complications of Allogenic Stem Cells Transplantation in Leukaemia
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure leukaemia. However, long term complications of post transplantation interfere with the patients’ full recovery. The objective of this review was to identify the various long term complications and to assess their individual prevalences.
Electronic databases including PubMed, Google Scholar and Cochrane were searched for years 2004–2017. The keywords used were leukaemia, allogenic stem cell transplantation, prevalence, side effects, long term, delayed, adverse effects, complications and outcome.
A total of ten articles were included for analysis. There were 5 prospective studies, 3 retrospective studies and 2 cross sectional studies. A total of 40,069 patients, (20,189 males and 17,191 females) participated in these 10 studies. The gender of 2689 patients were not disclosed. Most common late complications and prevalence were chronic graft versus host disease (43% at 5 years post HSCT), secondary tumor (21% at 20 years post HSCT), hypothyroidism (11% at 15 years), bronchiolitis obliterans (9.7% at 122 days), cardiovascular disease (7.5% at 15 years) and avascular necrosis (5.4% at 10 years). The prevalence of azoospermia was 71.1% and depression, 18%. For the latter two conditions no time limit was available. Follow up duration ranged from 2 years till 30 years post HSCT.
While allogenic stem cell transplantation is an effective cure for leukaemia, the procedure is associated with complications that can have their onset many years after the procedure.
KeywordsAllogenic stem cells Chronic graft Late complications Leukaemia
Associate Professor Dr. Sharmilla Kanagasundram acquisition, interpretation and analysis, drafting article and revising it for intellectual content. Associate Professor Farhanaz Amini concept and design of study and revising it for intellectual content.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
There are no animal experiments carried out for this article.
- 3.Mohty M, Apperley JF. Long-term physiological side effects after allogeneic bone marrow transplantation. Hematol Am Soc Hematol Educ Program. 2010;2010:229–36.Google Scholar
- 7.Friedman DL, Rovo A, Leisenring W, Locasciulli A, Flowers ME, Tichelli A, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood. 2008;111:939–44.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Yoshihara S, Tateisha U, Ando T, Kunitah H, Suyama H, Onishi Y, et al. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant. 2005;35:1195–2000.CrossRefPubMedGoogle Scholar
- 9.Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau JL, Masszi T, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:1203–10.CrossRefPubMedGoogle Scholar
- 11.Rovó A, Tichelli A, Passweg JR, Heim D, Meyer-Monard S, Holzgreve W, et al. Spermatogenesis in long-term survivors after allogenic haematopoietic stem cell transplantation is associated with age, time interval since transplantations, and apparently absence of chronic GvHD. Blood. 2006;108:1100–5.CrossRefPubMedGoogle Scholar
- 14.Vajdic CM, Mayson E, Dodds AJ, O'Brien T, Wilcox L, Nivison-Smith I, et al. Second cancer risk and late mortality in adult Australians receiving allogeneic hematopoietic stem cell transplantation: a population-based cohort study. Biol Blood Marrow Transplant. 2016;22:949–56.CrossRefPubMedGoogle Scholar
- 15.Chen D, Zhou D, Guo D, Xu P, Chen B. Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning: a meta-analysis. PLoS One. 2018;13:e0191955.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Cohen SB, Madrigal JA. Immunological and functional differences between cord and peripheral blood. Bone Marrow Transplant. 1998;21 Suppl 3:S9–12.Google Scholar
- 19.Tanimoto TE, Yamaguchi T, Tanaka Y, Saito A, Tajima K, Karasuno T, et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol. 2004;125:480–93.CrossRefPubMedGoogle Scholar
- 28.Kolb HJ, Socié G, Duell T, Van Lint MT, Tichelli A, Apperley JF, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med. 1999;131:738–44.CrossRefPubMedGoogle Scholar